bart van rhijn

[bart van rhijn @bartvanrhijn1]

@LifeSciVC Well said; Happy Thanksgiving to all and couldn't imagine another community to be working in!

[Nanobiotix @Nanobiotix]

We have just presented the first data from our Phase 1 study evaluating NBTXR3 for patients battling locally advanced pancreatic cancer at the 2023 Special Meeting on Pancreatic Cancer hosted by the American Association for Cancer Research. To learn more: https://t.co/h37d6wMTko

[Nanobiotix @Nanobiotix]

Take a deeper dive into Nanobiotix’s nanoparticle technology, our recent deal with Janssen, and the state of European biotech with Laurent Levy, our CEO during his interview with Brad Loncar from @BiotechTVHQ #biotech#endcancer
https://t.co/aDQvwgpJ9H]

[BiotechTV @BiotechTV]

Nanobiotix CEO Laurent Levy talks about his company’s nanoparticle technology, a recent deal with Janssen, and the state of European biotech. Full video: https://t.co/47e3XwMK3B

[bart van rhijn @bartvanrhijn1]

@QCompounding 👋

[Compounding Quality @QCompounding]

This PDF will teach you more than an MBA.

It will even make you smarter than most fund managers.

10.000 (!) pages full of investing wisdom from Warren Buffett, Terry Smith, Howard Marks and many more.

To receive it:
1️⃣ Follow us
2️⃣ Retweet this tweet
3️⃣ Reply 👋 below

[Nanobiotix @Nanobiotix]

Nanobiotix CEO Laurent Levy @nano_inmedicine and CFO Bart Van Rhijn @bartvanrhijn1 will participate in a virtual fireside chat during the 5th Annual @EvercoreISI HealthConx. Click to learn more https://t.co/2jdxbmpPkF

[Nanobiotix @Nanobiotix]

Nanobiotix is pleased to announce it has completion of the escalation part of a phase 1 study evaluating #NBTXR3 in pancreatic cancer. Check out our press release to learn more about the study, the recommended phase 2 dose, and next steps. #cancerpatients #feasibility #cancer

[Nanobiotix @Nanobiotix]

Nanobiotix is pleased to report updated anti-PD-1 combo data on the immune stimulation potential of NBTXR3 to be presented at the 37th annual @sitcancer meeting. https://t.co/1H08rfX7em Join us on the live webcast today at 8:00AM ET/2:00PM CET. #cancerpatients

[Nanobiotix @Nanobiotix]

To know more: https://t.co/7agA0sAK4S

[Nanobiotix @Nanobiotix]

We're back in-person at #BIO2022 to explore potentially limitless possibilities to improve cancer treatment. Meeting opportunities are available via the official BIO partnering site or you can contact us directly by following this link https://t.co/hz5xJxqRvz. #Limitlesstogether

[Nanobiotix @Nanobiotix]

Nanobiotix has announced that its Annual Combined Shareholders General Meeting will be held June 23 at 9:30AM CET/3:30AM EST. Documents/information concerning the meeting are available at https://t.co/FEKK56ySWU or upon request via [email protected]. #NBTX $NBTX

[Nanobiotix @Nanobiotix]

Don’t miss today’s presentation at @ASCO about the Phase 1b/2 study of NBTXR3 in combination with concurrent chemoradiation for locally advanced or unresectable rectal #cancer.$NBTX #NBTX

[Nanobiotix @Nanobiotix]

We're attending @ASCO and look forward to meeting you there! Secure a meeting with a member of our medical affairs team by sending us a DM. And discover more about what is being shared about #NBTXR3 this year by visiting https://t.co/TtNAB0YnHg #ASCO22 #ASCO

[Nanobiotix @Nanobiotix]

Following the announcement of our full-year 2021 financial results on March 30, a conference call/live audio webcast will follow on March 31 at 8am EDT/2pm CET. For dial-in information and to learn how to access the webcast, please visit: https://t.co/cgI5bxjkDl #NBTX $NBTX

[Nanobiotix @Nanobiotix]

Our CEO Laurent Levy wrote a @statnews First Opinion piece about why politicians in the US must fully fund programs that develop and scale innovative ideas. Do you agree? Comment below after reading the article! https://t.co/59pXBui0Zw @nano_inmedicine #NBTX #innovation

[Nanobiotix @Nanobiotix]

Nanobiotix wishes you and your family a very happy and healthy new year!

[Nanobiotix @Nanobiotix]

Nanobiotix announced the first-ever survival data evaluating #radioenhancer #NBTXR3 for high risk patients with head and neck cancer. What is a radioenhancer? How is it designed? Learn more: https://t.co/TZiiR59aMT #NBTX, $NBTX, #cancer, #radioenhancer, #radiationoncology, #HNSCC

[Nanobiotix @Nanobiotix]

Updated data from Nanobiotix Phase I Dose Expansion study evaluating #NBTXR3 show target lesion objective response rate of 85.4% and complete response rate of 63.4% in 41 evaluable #HNSCC patients. More: https://t.co/XcXj2l9tBI @ASTRO_org, #ASTRO21, #NBTX, #cancer, #radioenhancer

[Nanobiotix @Nanobiotix]

ANNOUNCEMENT: First survival data from Nanobiotix Phase I Dose Expansion in elderly and frail locally advanced #HNSCC patients presented at #ASTRO21. Learn more: https://t.co/XcXj2l9tBI @ASTRO_org, #NBTX, #cancer, #radioenhancer, #radiationoncology